Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
17 pending office actions • 11 art units • 15 examiners • 0 of 17 (0%) have an AI response strategy ready • 15 patents granted in the last 365 days
Bms currently has 17 pending office actions in the Biotechnology & Pharmaceuticals technology area. This portfolio size of 17 pending actions reflects an active engagement with the patent office to secure rights for pharmaceutical and biotechnological developments. The company's focus remains firmly within the Biotechnology & Pharmaceuticals sector for these active matters, indicating a specialized research and development pipeline.
The prosecution of these cases involves 15 distinct examiners across 11 distinct art units. With 17 pending office actions and 15 distinct examiners, the workload is largely decentralized, with only a few examiners handling more than one case. The 11 distinct art units involved indicate that the applications span several different specialized groups within the patent office's biotechnology divisions, requiring a strategy that accounts for varied departmental standards.
WEHBE, ANNE MARIE SABRINA is the busiest examiner for the portfolio, with 2 busiest examiner pending actions. These 2 pending actions represent a small fraction of the 17 total pending office actions, further emphasizing the distributed nature of the portfolio. This distribution suggests that the company's prosecution strategy must be adaptable to the varied requirements of 15 distinct examiners and the standards of 11 distinct art units to successfully advance its 17 total pending office actions.
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (6%) |
| §103 only | 4 (24%) |
| §112 only | 2 (12%) |
| Double-patenting only | 1 (6%) |
| Double-patenting + other | 5 (29%) |
| Multi-statute (no §101) | 4 (24%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WEHBE, ANNE MARIE SABRINA | 2 | 57.2% | +43.4% |
| CANELLA, KAREN A | 2 | 62.2% | +32.8% |
| SONG, HOON K | 1 | 86.3% | +8.3% |
| ZOU, NIANXIANG | 1 | 64.1% | +24.8% |
| METCALF, MATTHEW CURRAN | 1 | 37.5% | +71.4% |
| DUFFY, BRADLEY | 1 | 54.5% | +45.8% |
| GAO, ASHLEY HARTMAN | 1 | 56.7% | +38.2% |
| DUNN, LINDSAY MICHELLE | 1 | 80.0% | +0.0% |
| ZHU, JIANJIAN | 1 | 58.8% | +82.4% |
| CHANDRAKUMAR, NIZAL S | 1 | 72.7% | +18.3% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18908717 | METHODS FOR DETECTING PARTICLES PRESENT IN A CELL COMPOSITION | SONG, HOON K | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19570016 | METHODS FOR ISOLATING, CULTURING, AND GENETICALLY ENGINEERING IMMUNE CELL POPULATIONS FOR ADOPTIVE THERAPY | WEHBE, ANNE MARIE SABRINA | — |
| 18283435 | METHOD TO ASSESS POTENCY OF VIRAL VECTOR PARTICLES | ZOU, NIANXIANG | — |
| 18280197 | COMBINATION OF A T CELL THERAPY AND A DGK INHIBITOR | CANELLA, KAREN A | — |
| 18365950 | CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR GPRC5D AND BCMA | DUNN, LINDSAY MICHELLE | — |
| 18035277 | CELLS EXPRESSING A CHIMERIC RECEPTOR FROM A MODIFIED INVARIANT CD3 IMMUNOGLOBULIN SUPERFAMILY CHAIN LOCUS AND RELATED POLYNUCLEOTIDES AND METHODS | ZHU, JIANJIAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18188380 | METHODS AND COMPOSITIONS FOR DOSING IN ADOPTIVE CELL THERAPY | CANELLA, KAREN A | 63d |
| 18035280 | CAR T CELL THERAPY IN PATIENTS WHO HAVE HAD PRIOR ANTI-CANCER ALKYLATOR THERAPY | CHANDRAKUMAR, NIZAL S | 70d |
| 19570016 | METHODS FOR ISOLATING, CULTURING, AND GENETICALLY ENGINEERING IMMUNE CELL POPULATIONS FOR ADOPTIVE THERAPY | WEHBE, ANNE MARIE SABRINA | — |
| 19312145 | METHODS FOR ISOLATING, CULTURING, AND GENETICALLY ENGINEERING IMMUNE CELL POPULATIONS FOR ADOPTIVE THERAPY | WEHBE, ANNE MARIE SABRINA | — |
| 18283435 | METHOD TO ASSESS POTENCY OF VIRAL VECTOR PARTICLES | ZOU, NIANXIANG | — |
| 18518384 | OLIGOMERIC PARTICLE REAGENTS AND METHODS OF USE THEREOF | METCALF, MATTHEW CURRAN | — |
| 18491633 | METHODS AND COMPOSITIONS FOR ADOPTIVE CELL THERAPY | DUFFY, BRADLEY | — |
| 18283434 | METHODS OF DETERMINING POTENCY OF A THERAPEUTIC CELL COMPOSITION | GAO, ASHLEY HARTMAN | — |
| Art Unit | Apps |
|---|---|
| 1647 | 3 |
| 1643 | 3 |
| 1634 | 2 |
| 2884 | 1 |
| 1678 | 1 |
| 1644 | 1 |
| 1633 | 1 |
| 1625 | 1 |
| 1691 | 1 |
| 1642 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19570016 | METHODS FOR ISOLATING, CULTURING, AND GENETICALLY ENGINEERING IMMUNE CELL POPULATIONS FOR ADOPTIVE THERAPY | WEHBE, ANNE MARIE SABRINA | 1634 | §101Other | Final Rejection | — | Pending | Mar 17, 2026 |
| 19312145 | METHODS FOR ISOLATING, CULTURING, AND GENETICALLY ENGINEERING IMMUNE CELL POPULATIONS FOR ADOPTIVE THERAPY | WEHBE, ANNE MARIE SABRINA | 1634 | §103 | Non-Final OA | — | Pending | Aug 27, 2025 |
| 18908717 | METHODS FOR DETECTING PARTICLES PRESENT IN A CELL COMPOSITION | SONG, HOON K | 2884 | DP | Non-Final OA | — | Pending | Oct 07, 2024 |
| 18283435 | METHOD TO ASSESS POTENCY OF VIRAL VECTOR PARTICLES | ZOU, NIANXIANG | — | §103§112 | Non-Final OA | — | Pending | May 13, 2024 |
| 18518384 | OLIGOMERIC PARTICLE REAGENTS AND METHODS OF USE THEREOF | METCALF, MATTHEW CURRAN | 1647 | §103 | Non-Final OA | — | Pending | Nov 22, 2023 |
| 18491633 | METHODS AND COMPOSITIONS FOR ADOPTIVE CELL THERAPY | DUFFY, BRADLEY | 1643 | §103 | Final Rejection | — | Pending | Oct 20, 2023 |
| 18283434 | METHODS OF DETERMINING POTENCY OF A THERAPEUTIC CELL COMPOSITION | GAO, ASHLEY HARTMAN | 1678 | §103§112DP | Non-Final OA | — | Pending | Sep 21, 2023 |
| 18280197 | COMBINATION OF A T CELL THERAPY AND A DGK INHIBITOR | CANELLA, KAREN A | 1643 | §102§103§112 | Non-Final OA | — | Pending | Sep 01, 2023 |
| 18365950 | CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR GPRC5D AND BCMA | DUNN, LINDSAY MICHELLE | 1644 | §103§112 | Non-Final OA | — | Pending | Aug 04, 2023 |
| 18035277 | CELLS EXPRESSING A CHIMERIC RECEPTOR FROM A MODIFIED INVARIANT CD3 IMMUNOGLOBULIN SUPERFAMILY CHAIN LOCUS AND RELATED POLYNUCLEOTIDES AND METHODS | ZHU, JIANJIAN | 1633 | §103§112 | Non-Final OA | — | Pending | May 03, 2023 |
| 18035280 | CAR T CELL THERAPY IN PATIENTS WHO HAVE HAD PRIOR ANTI-CANCER ALKYLATOR THERAPY | CHANDRAKUMAR, NIZAL S | 1625 | §112Other | Final Rejection | 70d | Pending | May 03, 2023 |
| 18188380 | METHODS AND COMPOSITIONS FOR DOSING IN ADOPTIVE CELL THERAPY | CANELLA, KAREN A | 1643 | §102§103§112DPOther | Non-Final OA | 63d | Pending | Mar 22, 2023 |
| 18019460 | ANTI-IDIOTYPIC ANTIBODIES TO ROR1-TARGETED BINDING DOMAINS AND RELATED COMPOSITIONS AND METHODS | SUNSHINE, HANNAH LOUISE | 1647 | §112 | Non-Final OA | 8d overdue | Pending | Feb 02, 2023 |
| 17921614 | COMBINATION OF BCMA-DIRECTED T CELL THERAPY AND AN IMMUNOMODULATORY COMPOUND | JOHNSON, CHRISTOPHER LINDSAY | 1691 | §103DP | Non-Final OA | 26d | Pending | Oct 26, 2022 |
| 17774821 | COMBINATION OF A T CELL THERAPY AND (S)-3-[4-(4-MORPHOLIN-4-YLMETHYL-BENZYLOXY)-L-OXO-L,3-DIHYDRO-ISOINDOL-2-YL]-PIPERIDINE-2,6-DIONE | BUTTICE, AUDREY L | 1647 | §103Other | Final Rejection | — | Pending | May 05, 2022 |
| 17297771 | METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY | LU, CHENG | 1642 | §103DP | Final Rejection | — | Pending | May 27, 2021 |
| 17291536 | PROCESS FOR PRODUCING GENETICALLY ENGINEERED T CELLS | VAN BUREN, LAUREN K | 1638 | §103§112DP | Final Rejection | 19d | Pending | May 05, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial